194 related articles for article (PubMed ID: 7768585)
1. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension.
Gradman AH; Arcuri KE; Goldberg AI; Ikeda LS; Nelson EB; Snavely DB; Sweet CS
Hypertension; 1995 Jun; 25(6):1345-50. PubMed ID: 7768585
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension.
Tikkanen I; Omvik P; Jensen HA
J Hypertens; 1995 Nov; 13(11):1343-51. PubMed ID: 8984133
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of losartan versus enalapril alone or in combination with hydrochlorothiazide in patients with essential hypertension.
Townsend R; Haggert B; Liss C; Edelman JM
Clin Ther; 1995; 17(5):911-23. PubMed ID: 8595643
[TBL] [Abstract][Full Text] [Related]
4. Comparative effects of combination drug therapy regimens commencing with either losartan potassium, an angiotensin II receptor antagonist, or enalapril maleate for the treatment of severe hypertension.
Ruff D; Gazdick LP; Berman R; Goldberg AI; Sweet CS
J Hypertens; 1996 Feb; 14(2):263-70. PubMed ID: 8728306
[TBL] [Abstract][Full Text] [Related]
5. An inpatient trial of the safety and efficacy of losartan compared with placebo and enalapril in patients with essential hypertension.
Byyny RL; Merrill DD; Bradstreet TE; Sweet CS
Cardiovasc Drugs Ther; 1996 Jul; 10(3):313-9. PubMed ID: 8877074
[TBL] [Abstract][Full Text] [Related]
6. Comparative antihypertensive effects of losartan 50 mg and losartan 50 mg titrated to 100 mg in patients with essential hypertension.
Ikeda LS; Harm SC; Arcuri KE; Goldberg AI; Sweet CS
Blood Press; 1997 Jan; 6(1):35-43. PubMed ID: 9116924
[TBL] [Abstract][Full Text] [Related]
7. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components.
MacKay JH; Arcuri KE; Goldberg AI; Snapinn SM; Sweet CS
Arch Intern Med; 1996 Feb; 156(3):278-85. PubMed ID: 8572837
[TBL] [Abstract][Full Text] [Related]
8. Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients.
Goldberg MR; Bradstreet TE; McWilliams EJ; Tanaka WK; Lipert S; Bjornsson TD; Waldman SA; Osborne B; Pivadori L; Lewis G
Hypertension; 1995 Jan; 25(1):37-46. PubMed ID: 7843751
[TBL] [Abstract][Full Text] [Related]
9. Randomised, double-blind, parallel study of the anti-hypertensive efficacy and safety of losartan potassium compared with felodipine ER in elderly patients with mild to moderate hypertension.
Chan JC; Critchley JA; Lappe JT; Raskin SJ; Snavely D; Goldberg AI; Sweet CS
J Hum Hypertens; 1995 Sep; 9(9):765-71. PubMed ID: 8551492
[TBL] [Abstract][Full Text] [Related]
10. Randomized, double-blind comparison of irbesartan and enalapril for treatment of mild to moderate hypertension.
Chiou KR; Chen CH; Ding PY; Chen YT; Ting CT; Huang JL; Chiang AH; Liu CP; Tseng CJ; Chao CT; Chang MS
Zhonghua Yi Xue Za Zhi (Taipei); 2000 May; 63(5):368-76. PubMed ID: 10862446
[TBL] [Abstract][Full Text] [Related]
11. Blood pressure effects of the angiotensin II receptor blocker, losartan.
Weber MA; Byyny RL; Pratt JH; Faison EP; Snavely DB; Goldberg AI; Nelson EB
Arch Intern Med; 1995 Feb; 155(4):405-11. PubMed ID: 7848024
[TBL] [Abstract][Full Text] [Related]
12. An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan. Irbesartan/Losartan Study Investigators.
Oparil S; Guthrie R; Lewin AJ; Marbury T; Reilly K; Triscari J; Witcher JA
Clin Ther; 1998; 20(3):398-409. PubMed ID: 9663357
[TBL] [Abstract][Full Text] [Related]
13. A randomised, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension.
Mimran A; Ruilope L; Kerwin L; Nys M; Owens D; Kassler-Taub K; Osbakken M
J Hum Hypertens; 1998 Mar; 12(3):203-8. PubMed ID: 9579771
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of losartan.
Goldberg A; Sweet C
Can J Cardiol; 1995 Aug; 11 Suppl F():27F-32F. PubMed ID: 7664215
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy and safety of olmesartan medoxomil versus losartan potassium in Chinese patients with mild to moderate essential hypertension].
Zhu JR; Cai NS; Fan WH; Zhu DL; He B; Wu ZG; Ke YN; Guo JX; Ma H; Huang J; Li XL; Chen YZ
Zhonghua Xin Xue Guan Bing Za Zhi; 2006 Oct; 34(10):877-81. PubMed ID: 17217710
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of efficacy and safety of losartan potassium in the treatment of mild to moderate hypertension as compared to enalapril maleate.
Shobha JC; Kumar TR; Raju BS; Kamath S; Rao M; Harwal ; Babu A; Bhaduri J
J Assoc Physicians India; 2000 May; 48(5):497-500. PubMed ID: 11273142
[TBL] [Abstract][Full Text] [Related]
17. The clinical efficacy and tolerability of the angiotensin II-receptor antagonist losartan in Japanese patients with hypertension.
Ogihara T; Yoshinaga K
Blood Press Suppl; 1996; 2():78-81. PubMed ID: 8913545
[TBL] [Abstract][Full Text] [Related]
18. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril.
Holwerda NJ; Fogari R; Angeli P; Porcellati C; Hereng C; Oddou-Stock P; Heath R; Bodin F
J Hypertens; 1996 Sep; 14(9):1147-51. PubMed ID: 8986917
[TBL] [Abstract][Full Text] [Related]
19. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan.
Smith DH; Dubiel R; Jones M
Am J Cardiovasc Drugs; 2005; 5(1):41-50. PubMed ID: 15631537
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension.
Lee SE; Kim YJ; Lee HY; Yang HM; Park CG; Kim JJ; Kim SK; Rhee MY; Oh BH;
Clin Ther; 2012 Mar; 34(3):552-568, 568.e1-9. PubMed ID: 22381711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
